Literature DB >> 26870765

Hepatitis E In Transplant Recipients: Why Is This Not A Problem In Japan?

Sven Pischke1, Heiner Wedemeyer2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26870765      PMCID: PMC4740336          DOI: 10.1016/j.ebiom.2015.11.013

Source DB:  PubMed          Journal:  EBioMedicine        ISSN: 2352-3964            Impact factor:   8.143


× No keyword cloud information.
Chronic hepatitis E virus (HEV) infection in immunosuppressed patients is increasingly recognized as a relevant clinical problem in European countries. However, it is unclear whether chronic hepatitis E is also a potential problem in eastern Asia. The study by lInagaki et al. published in this issue of EBioMedicine is therefore of major interest (Inagaki et al., 2015). The authors performed a large multi-center study examining the frequency and clinical relevance of chronic hepatitis E in Japanese liver transplant recipients. About 75% of all liver transplant centers participated in this study, comprising HEV-RNA testing of 1651 liver transplant recipients. Of note and very importantly, only two chronic HEV infections were detected, which is a surprisingly low rate of HEV infected patients (0.12%). The finding is remarkable considering that the median time from transplantation was 81 months (range 0–297 months) representing a long time of potential exposure post-transplantation. The findings in Japan are quite different from European experiences where many studies describe frequencies of chronic hepatitis E of more than 1% in liver transplant cohorts (Fig. 1) (Behrendt et al., 2014). In contrast, no case of chronic hepatitis E was found in India in a study on 205 renal transplant recipients (Naik et al., 2013). This has led to the hypothesis that HEV genotype 1, which is common in India, may not cause chronic infection. However, most reported cases of chronic hepatitis E are associated with HEV genotype 3 infections, and more rarely HEV genotype 4. In Japan, HEV genotypes 3 and 4 are endemic (Okano et al., 2014). The HEV subtype 3e is most frequently found in Japan (Okano et al., 2014), as in Central Europe. HEV genotypes or subtypes are therefore unlikely to explain the apparent differences in chronic HEV frequencies — even though it is still possible that distinct HEV strains circulating in Japan may be less likely to cause chronicity.
Fig. 1

Chronic hepatitis E in Japanese liver transplant recipients is less common than in Europe (Behrendt et al., 2014).

What then could explain the very low frequency of chronic hepatitis E in Japan (Fig. 1)? First, it is possible that distinct genetic factors in the Japanese population confer some level of resistance to chronic HEV infection. For other infections such as hepatitis C, differences in interferon-lambda 3 genotypes between Asians and Caucasians indeed explain, to some extent, distinct outcomes in these populations (Thursz et al., 2011). Second, there are obvious differences in food consumption habits between Japan and Europe. Regarding HEV infection, food products containing raw or undercooked pork meat are particular popular in some European countries and thus exposure to HEV may be more likely. Third, blood products may be less likely to carry HEV in Japan than in Europe (Hewitt et al., 2014). Of note, HEV-IgG antibodies have been shown to be lower in Japan (6%) than in Korean Chinese (51%), indigenous Chinese (48%), South Koreans (34%) or Koreans living in Japan (14%) (Taniguchi et al., 2009). In summary, Inagaki et al. demonstrated for the first time that chronic hepatitis E also occurs in Japan, albeit at a far lower frequency than in European transplant cohorts. The explanation for this difference still needs to be defined.
  6 in total

Review 1.  Understanding the host genetics of chronic hepatitis B and C.

Authors:  Mark Thursz; Leland Yee; Salim Khakoo
Journal:  Semin Liver Dis       Date:  2011-05-02       Impact factor: 6.115

2.  Lack of evidence of hepatitis E virus infection among renal transplant recipients in a disease-endemic area.

Authors:  A Naik; N Gupta; D Goel; S K Ippagunta; R K Sharma; R Aggarwal
Journal:  J Viral Hepat       Date:  2012-11-26       Impact factor: 3.728

3.  Characterization of sporadic acute hepatitis E and comparison of hepatitis E virus genomes in acute hepatitis patients and pig liver sold as food in Mie, Japan.

Authors:  Hiroshi Okano; Masaharu Takahashi; Yoshiaki Isono; Hiroki Tanaka; Tatsunori Nakano; Yumi Oya; Kazushi Sugimoto; Keiichi Ito; Shigeru Ohmori; Tadashi Maegawa; Makoto Kobayashi; Shigeo Nagashima; Tsutomu Nishizawa; Hiroaki Okamoto
Journal:  Hepatol Res       Date:  2013-09-12       Impact factor: 4.288

Review 4.  The impact of hepatitis E in the liver transplant setting.

Authors:  Patrick Behrendt; Eike Steinmann; Michael P Manns; Heiner Wedemeyer
Journal:  J Hepatol       Date:  2014-09-06       Impact factor: 25.083

5.  Epidemiology of hepatitis E in Northeastern China, South Korea and Japan.

Authors:  Miyuki Taniguchi; Soo Ryang Kim; Shunji Mishiro; Kazuaki Takahashi; Myung Hee Shin; Haesun Yun; Man Suk Park; Zhong Min Li; Mi Kyung Kim; Jinnv Fang; Yoshitake Hayashi
Journal:  J Infect       Date:  2009-02-26       Impact factor: 6.072

6.  Hepatitis E virus in blood components: a prevalence and transmission study in southeast England.

Authors:  Patricia E Hewitt; Samreen Ijaz; Su R Brailsford; Rachel Brett; Steven Dicks; Becky Haywood; Iain T R Kennedy; Alan Kitchen; Poorvi Patel; John Poh; Katherine Russell; Kate I Tettmar; Joanne Tossell; Ines Ushiro-Lumb; Richard S Tedder
Journal:  Lancet       Date:  2014-07-28       Impact factor: 79.321

  6 in total
  4 in total

Review 1.  Acute and Persistent Hepatitis E Virus Genotype 3 and 4 Infection: Clinical Features, Pathogenesis, and Treatment.

Authors:  Nassim Kamar; Sven Pischke
Journal:  Cold Spring Harb Perspect Med       Date:  2019-07-01       Impact factor: 6.915

2.  Comprehensive Molecular Approach for Characterization of Hepatitis E Virus Genotype 3 Variants.

Authors:  Bo Wang; Dominik Harms; C Patrick Papp; Sandra Niendorf; Sonja Jacobsen; Marc Lütgehetmann; Sven Pischke; Heiner Wedermeyer; Jörg Hofmann; C-Thomas Bock
Journal:  J Clin Microbiol       Date:  2018-04-25       Impact factor: 5.948

Review 3.  Hepatitis E: Still Waters Run Deep.

Authors:  Moritz von Wulffen; Dirk Westhölter; Marc Lütgehetmann; Sven Pischke
Journal:  J Clin Transl Hepatol       Date:  2017-09-21

Review 4.  Clinical Manifestations, Pathogenesis and Treatment of Hepatitis E Virus Infections.

Authors:  Sébastien Lhomme; Olivier Marion; Florence Abravanel; Jacques Izopet; Nassim Kamar
Journal:  J Clin Med       Date:  2020-01-24       Impact factor: 4.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.